(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
A Manual for Pick Great Lawful Discussion Administrations For New businesses In 2024 - 2Attorney-General to High Court: Gov’t violating draft ruling, risking rule of law
- 3Dental Embed Developments: Upsetting Current Dentistry
- 4Wedding trip Objections in Europe
- 5At least 171 measles cases confirmed in 9 states, CDC data shows
- Grasping the Basics of Business Land Regulation
- 10 Delectable Specialty Mixed drinks
- What will the Artemis 2 astronauts eat during their historic moon mission? (video)
- Melodic Event: A Survey of \Energies and Exhibitions Assessed\ Live concert
- Volcanic eruption led to the Black Death, new research suggests
- Figure out how to Team up with Your Auto Crash Legal advisor for Best Outcomes
- Believe Should Unwind? Look at These Scaled down Games
- How stripping diversity, equity and inclusion from health care may make Americans sicker
- Anthony Joshua's driver charged over Nigeria crash that killed two
